COMBINATION CELL IMMUNOTHERAPY OF MALIGNANT TUMORS Russian patent published in 2023 - IPC A61K35/15 A61K35/17 A61P35/00 

FIELD: medicine; oncology; immunology; tumor immunology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology, immunology, and tumor immunology; it is intended for the prevention of progression and relapse of malignant neoplasms. A method for combination adoptive cell immunotherapy of malignant neoplasms for the prevention of their progression and relapse in patients with the absence of inflammatory foci of a non-oncological nature includes subsequent administration to a patient of a dendritic cell vaccine (hereinafter – DCV) stimulating specific antitumor immunity and NKG2D-expressing cytotoxic T-lymphocyte (hereinafter – NKG2D+CTL) drug capable of killing tumor cells in a non-specific way. DCV is administered at an interval of 2-4 weeks, and NKG2D+CTL is administered the day after administration of DCV. The specified NKG2D+CTL drug and its production method are also provided.

EFFECT: use of the group of inventions provides for efficient prevention of malignant neoplasms after removal of the main tumor mass (cytoreduction) and completion of cytostatic and cytotoxic treatment.

7 cl, 2 dwg, 8 tbl, 2 ex